vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是RE/MAX Holdings, Inc.的1.1倍（$75.5M vs $71.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -4.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
PBYI vs RMAX — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$71.1M
营收增速更快
PBYI
高出29.6%
-1.8%
自由现金流更多
RMAX
多$19.1M
$14.4M
两年增速更快
PBYI
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 27.7% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIRMAX
| Q4 25 | $75.5M | $71.1M | ||
| Q3 25 | $54.5M | $73.2M | ||
| Q2 25 | $52.4M | $72.8M | ||
| Q1 25 | $46.0M | $74.5M | ||
| Q4 24 | $59.1M | $72.5M | ||
| Q3 24 | $80.5M | $78.5M | ||
| Q2 24 | $47.1M | $78.5M | ||
| Q1 24 | $43.8M | $78.3M |
净利润PBYIRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $8.8M | $4.0M | ||
| Q2 25 | $5.9M | $4.7M | ||
| Q1 25 | $3.0M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $20.3M | $966.0K | ||
| Q2 24 | $-4.5M | $3.7M | ||
| Q1 24 | $-4.8M | $-3.4M |
毛利率PBYIRMAX
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIRMAX
| Q4 25 | 22.7% | 13.1% | ||
| Q3 25 | 17.6% | 25.0% | ||
| Q2 25 | 12.7% | 19.3% | ||
| Q1 25 | 8.7% | 7.2% | ||
| Q4 24 | 22.6% | 5.9% | ||
| Q3 24 | 27.4% | 19.4% | ||
| Q2 24 | -4.6% | 20.6% | ||
| Q1 24 | -5.3% | 5.8% |
净利率PBYIRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | 16.2% | 5.4% | ||
| Q2 25 | 11.2% | 6.4% | ||
| Q1 25 | 6.5% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 25.2% | 1.2% | ||
| Q2 24 | -9.6% | 4.7% | ||
| Q1 24 | -11.0% | -4.3% |
每股收益（稀释后）PBYIRMAX
| Q4 25 | $0.26 | — | ||
| Q3 25 | $0.17 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $118.7M |
| 总债务越低越好 | $22.7M | $432.2M |
| 股东权益账面价值 | $130.3M | $452.4M |
| 总资产 | $216.3M | $582.5M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资PBYIRMAX
| Q4 25 | $97.5M | $118.7M | ||
| Q3 25 | $94.4M | $107.5M | ||
| Q2 25 | $96.0M | $94.3M | ||
| Q1 25 | $93.2M | $89.1M | ||
| Q4 24 | $101.0M | $96.6M | ||
| Q3 24 | $96.7M | $83.8M | ||
| Q2 24 | $96.8M | $66.1M | ||
| Q1 24 | $107.2M | $82.1M |
总债务PBYIRMAX
| Q4 25 | $22.7M | $432.2M | ||
| Q3 25 | $34.0M | $433.3M | ||
| Q2 25 | $45.3M | $434.4M | ||
| Q1 25 | $56.7M | $435.3M | ||
| Q4 24 | $68.0M | $436.2M | ||
| Q3 24 | $79.3M | $437.2M | ||
| Q2 24 | $90.7M | $438.1M | ||
| Q1 24 | $102.0M | $439.0M |
股东权益PBYIRMAX
| Q4 25 | $130.3M | $452.4M | ||
| Q3 25 | $115.3M | $448.1M | ||
| Q2 25 | $104.7M | $442.4M | ||
| Q1 25 | $97.1M | $433.5M | ||
| Q4 24 | $92.1M | $429.5M | ||
| Q3 24 | $71.1M | $423.1M | ||
| Q2 24 | $48.5M | $418.4M | ||
| Q1 24 | $51.0M | $412.0M |
总资产PBYIRMAX
| Q4 25 | $216.3M | $582.5M | ||
| Q3 25 | $202.9M | $582.2M | ||
| Q2 25 | $194.9M | $574.8M | ||
| Q1 25 | $196.2M | $571.4M | ||
| Q4 24 | $213.3M | $581.6M | ||
| Q3 24 | $220.7M | $578.6M | ||
| Q2 24 | $205.0M | $571.4M | ||
| Q1 24 | $214.1M | $566.7M |
负债/权益比PBYIRMAX
| Q4 25 | 0.17× | 0.96× | ||
| Q3 25 | 0.30× | 0.97× | ||
| Q2 25 | 0.43× | 0.98× | ||
| Q1 25 | 0.58× | 1.00× | ||
| Q4 24 | 0.74× | 1.02× | ||
| Q3 24 | 1.12× | 1.03× | ||
| Q2 24 | 1.87× | 1.05× | ||
| Q1 24 | 2.00× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $33.5M |
| 自由现金流率自由现金流/营收 | 19.1% | 47.1% |
| 资本支出强度资本支出/营收 | 0.0% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $56.8M |
8季度趋势，按日历期对齐
经营现金流PBYIRMAX
| Q4 25 | $14.4M | $40.9M | ||
| Q3 25 | $9.7M | $17.7M | ||
| Q2 25 | $14.1M | $4.6M | ||
| Q1 25 | $3.6M | $5.7M | ||
| Q4 24 | $15.6M | $59.7M | ||
| Q3 24 | $11.0M | $17.6M | ||
| Q2 24 | $1.0M | $15.9M | ||
| Q1 24 | $11.2M | $9.4M |
自由现金流PBYIRMAX
| Q4 25 | $14.4M | $33.5M | ||
| Q3 25 | $9.7M | $16.4M | ||
| Q2 25 | $14.1M | $2.9M | ||
| Q1 25 | $3.6M | $4.0M | ||
| Q4 24 | $15.6M | $53.0M | ||
| Q3 24 | $11.0M | $16.3M | ||
| Q2 24 | $1.0M | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率PBYIRMAX
| Q4 25 | 19.1% | 47.1% | ||
| Q3 25 | 17.7% | 22.4% | ||
| Q2 25 | 26.8% | 4.0% | ||
| Q1 25 | 7.7% | 5.3% | ||
| Q4 24 | 26.4% | 73.2% | ||
| Q3 24 | 13.7% | 20.8% | ||
| Q2 24 | 2.1% | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度PBYIRMAX
| Q4 25 | 0.0% | 10.4% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.1% | 2.3% | ||
| Q4 24 | 0.0% | 9.1% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.0% | 3.3% |
现金转化率PBYIRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | 1.10× | 4.45× | ||
| Q2 25 | 2.41× | 0.97× | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 0.54× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
